Lipid peroxidation in proliferative vitreoretinopathies - PubMed (original) (raw)

. 1999 Apr:13 ( Pt 2):183-8.

doi: 10.1038/eye.1999.48.

Affiliations

• PMID: 10450379
• DOI: 10.1038/eye.1999.48

Lipid peroxidation in proliferative vitreoretinopathies

C Verdejo et al. Eye (Lond). 1999 Apr.

Abstract

Purpose: To study the lipid hydroperoxide activity in vasoproliferative and fibroproliferative retinal disorders.

Methods: Vitreous body samples from patients undergoing vitrectomy because of proliferative vitreoretinopathy (PVR; n = 12) or proliferative diabetic retinopathy (PDR; n = 15), and rhegmatogenous retinal detachment/macular hole/epiretinal membranes as the comparison group (CG; n = 14), were analysed for protein content and basal and induced lipid peroxidation (LPO), as determined by the thiobarbituric acid reactive substances (TBARS) test and LPO 586 commercial kit. The antioxidant activity for superoxide dismutase (SOD) and catalase (CAT) was also assayed.

Results: Malondialdehyde (MDA)-like metabolites and 4-hydroxynonenal (4-HNE) mean values were first measured to assess basal LPO, and found to be significantly higher in the PVR and PDR cases than in the CG (p < or = 0.0001). LPO induced by nicotine adenine dinucleotide phosphate iron (NADPH-Fe) was then assayed and the data showed that MDA mean values were 5-fold greater for the PVR and PDR eyes than in the case of basal LPO (p < or = 0.0001). SOD activity was significantly smaller in the PVR (p = 0.0010) and PDR (p < or = 0.0001) groups than in the CG. CAT levels displayed significantly lower values in the PVR and PDR cases than in the CG (p < or = 0.0001). No significant differences in free radical (FR) formation and antioxidant status between PVR and PDR patients were observed.

Conclusions: Fibrovascular proliferative vitreoretinopathies correlate with increased FR formation and decreased antioxidant activity in the human vitreous body.

PubMed Disclaimer

Similar articles

• Upregulation of RAGE and its ligands in proliferative retinal disease.
  Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR. Pachydaki SI, et al. Exp Eye Res. 2006 May;82(5):807-15. doi: 10.1016/j.exer.2005.09.022. Epub 2005 Dec 20. Exp Eye Res. 2006. PMID: 16364297
• Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
  Citirik M, Kabatas EU, Batman C, Akin KO, Kabatas N. Citirik M, et al. Ophthalmic Res. 2012;47(1):7-12. doi: 10.1159/000324200. Epub 2011 Jun 21. Ophthalmic Res. 2012. PMID: 21691136
• Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
  Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J. Abu El-Asrar AM, et al. Eur Cytokine Netw. 2006 Sep;17(3):155-65. Eur Cytokine Netw. 2006. PMID: 17194635
• Soluble TNF receptors in vitreoretinal proliferative disease.
  Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Limb GA, et al. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1586-91. Invest Ophthalmol Vis Sci. 2001. PMID: 11381065

Cited by

• Antioxidant Status in the Vitreous of Eyes with Rhegmatogenous Retinal Detachment with and without Proliferative Vitreoretinopathy, Macular Hole and Epiretinal Membrane.
  Pietras-Baczewska A, Nowomiejska K, Brzozowska A, Toro MD, Załuska W, Sztanke M, Sztanke K, Rejdak R. Pietras-Baczewska A, et al. Life (Basel). 2021 May 19;11(5):453. doi: 10.3390/life11050453. Life (Basel). 2021. PMID: 34069386 Free PMC article.
• Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients.
  Izuta H, Chikaraishi Y, Adachi T, Shimazawa M, Sugiyama T, Ikeda T, Hara H. Izuta H, et al. Mol Vis. 2009 Dec 10;15:2663-72. Mol Vis. 2009. PMID: 20011081 Free PMC article.
• Lipid peroxidation and total antioxidant capacity in vitreous, aqueous humor, and blood samples from patients with diabetic retinopathy.
  Mancino R, Di Pierro D, Varesi C, Cerulli A, Feraco A, Cedrone C, Pinazo-Duran MD, Coletta M, Nucci C. Mancino R, et al. Mol Vis. 2011;17:1298-304. Epub 2011 May 7. Mol Vis. 2011. PMID: 21633716 Free PMC article.
• The Effect of Vitamin E on Oxidative Stress Indicated by Serum Malondialdehyde in Insulin-dependent Type 2 Diabetes Mellitus Patients with Retinopathy.
  Chatziralli IP, Theodossiadis G, Dimitriadis P, Charalambidis M, Agorastos A, Migkos Z, Platogiannis N, Moschos MM, Theodossiadis P, Keryttopoulos P. Chatziralli IP, et al. Open Ophthalmol J. 2017 Mar 31;11:51-58. doi: 10.2174/1874364101711010051. eCollection 2017. Open Ophthalmol J. 2017. PMID: 28567166 Free PMC article.
• Clinical and Molecular-Genetic Insights into the Role of Oxidative Stress in Diabetic Retinopathy: Antioxidant Strategies and Future Avenues.
  Sanz-González SM, García-Medina JJ, Zanón-Moreno V, López-Gálvez MI, Galarreta-Mira D, Duarte L, Valero-Velló M, Ramírez AI, Arévalo JF, Pinazo-Durán MD, On Behalf Of The Valencia Study Group On Diabetic Retinopathy Vsdr Report Number. Sanz-González SM, et al. Antioxidants (Basel). 2020 Nov 9;9(11):1101. doi: 10.3390/antiox9111101. Antioxidants (Basel). 2020. PMID: 33182408 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal